Merck’s Ebola Vaccine Found to Be Effective by Expert Panel

Updated on

Ebola Vaccine 'Highly Effective' Trial Should Continue

Merck & Co.’s vaccine for Ebola is “highly effective,” according to an interim analysis from a panel of experts who recommended that a late-stage trial should continue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.